Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
estimated completion
Principal Investigator
by Zev Wainberg (ucla)

Description

Summary

This Phase 1 study is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of AMV564 alone and in combination with Pembrolizumab in patients with advanced solid tumors.

Official Title

A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Details

AMV564-301 is a Phase 1, open-label, multicenter dose-escalation with expansion trial in patients with locally advanced or metastatic solid tumors. In the dose-escalation portion of the study, cohorts of patients will receive AMV564 alone or in combination with Pembrolizumab at increasing dose levels to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion. In the expansion portion of the study, one or more cohorts of patients will receive AMV564 at the MTD or recommended dose to further evaluate safety, tolerability, and clinical activity.

Keywords

Locally Advanced or Metastatic Solid Tumors immunotherapy anti-CD33 T-cell engager Neoplasms AMV564

Eligibility

You can join if…

Open to people ages 18 years and up

  • 18 years of age or older
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Histologically or cytologically documented, incurable or metastatic solid tumor that is advanced (non-resectable) or recurrent and progressing since the last anti-tumor therapy and for which no recognized standard therapy exists
  • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or per other criteria best suited for the specific tumor type being evaluated
  • Willing to complete all scheduled visits and assessments at the institution administering therapy

You CAN'T join if...

  • Treatment with any local or systemic antineoplastic therapy (including chemotherapy, hormonal therapy, or radiation) within 3 weeks prior to first dose of AMV564
  • Major trauma or major surgery within 4 weeks prior to first dose of AMV564
  • Prior treatment with chimeric antigen receptor (CAR) T-cell therapy or T-cell engager therapy
  • Chronic use of corticosteroids in excess of 10 mg daily of prednisone or equivalent within 4 weeks prior to first dose of AMV564
  • Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1 except for alopecia
  • Known, central nervous system (CNS) disease involvement, or prior history of National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Grade ≥ 3 drug-related CNS toxicity

Locations

  • UCLA accepting new patients
    Los Angeles California 90095 United States
  • NEXT Oncology accepting new patients
    San Antonio Texas 78229 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Amphivena Therapeutics, Inc.
ID
NCT04128423
Phase
Phase 1
Study Type
Interventional
Last Updated